Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients

doi:10.1002/cam4.5357

	Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients
	Hao, Yue 1,6; Lin, Gen 7; Xiang, Jing 1; Wang, Wenxian 1; Xu, Chunwei 2; Wang, Qian 4; Cai, Jing 3; Zhang, Yongchang 5; Song, Zhengbo 1
刊名	CANCER MEDICINE
	2022-11-16
关键词	efficacy immune-related adverse events immunotherapy thymoma
ISSN号	2045-7634
DOI	10.1002/cam4.5357
通讯作者	Song, Zhengbo(songzb@zjcc.org.cn)
英文摘要	Background Immunotherapy has exhibited efficacy in thymic carcinoma patients; however, there are insufficient data to confirm this efficacy in thymoma. The toxicity of immunotherapy also remains to be determined. Methods The efficacy and safety of immunotherapy were analyzed in 11 thymoma patients who received PD-1 inhibitors according to a range of relevant indexes including the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and immunotherapy-related adverse events. Results The PFS and OS rates for all patients were 12.8 and 56.5 months, respectively. No difference in efficacy was detected between monotherapy and combination therapy (PFS: 12.8 vs 2.2 months, P = 0.787; OS: 73.8 vs 56.5 months, P = 0.367). The ORRs and DCRs for all patients were 27.3% and 90.9%, respectively. The incidence of adverse events was 45.5% among the 11 thymoma patients, including immune-related myocarditis (36.4%), immune-related liver damage (18.2%), and myasthenia gravis (18.2%). In the whole cohort of patients, the rate of adverse events of grade 3 or higher was 36.4%. The rates of adverse events of grade 3 or 4 in B3-type and non-B3-type thymoma patients were 0% and 62.5%, respectively. Conclusions Immunotherapy elicited a response in thymoma patients; however, more attention should be paid to the immune-related adverse events.
资助项目	Foundation of CSCO-Shiyao[Y-SY201901-0068] ; Zhejiang provincial program for the Cultivation of High-level Innovative Health talents
WOS关键词	THYMIC CARCINOMA ; PEMBROLIZUMAB ; CHEMOTHERAPY ; CISPLATIN
WOS研究方向	Oncology
语种	英语
出版者	WILEY
WOS记录号	WOS:000884642300001
资助机构	Foundation of CSCO-Shiyao ; Zhejiang provincial program for the Cultivation of High-level Innovative Health talents
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/130295]
专题	中国科学院合肥物质科学研究院
通讯作者	Song, Zhengbo
作者单位	1.Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Zhejiang Canc Hosp, Hangzhou, Peoples R China 2.Nanjing Univ, Dept Resp Med, Jinling Hosp, Sch Med, Nanjing, Peoples R China 3.Nanchang Univ, Dept Oncol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China 4.Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Dept Resp Med, Nanjing, Peoples R China 5.Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp,Dept Med Oncol, Hunan Canc Hosp,Lung Canc & Gastrointestinal Unit, Changsha, Peoples R China 6.Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Zhejiang, Peoples R China 7.Fujian Med Univ Canc Hosp, Dept Thorac Oncol, Fujian Canc Hosp, Fuzhou, Peoples R China
推荐引用方式 GB/T 7714	Hao, Yue,Lin, Gen,Xiang, Jing,et al. Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients[J]. CANCER MEDICINE,2022.
APA	Hao, Yue.,Lin, Gen.,Xiang, Jing.,Wang, Wenxian.,Xu, Chunwei.,...&Song, Zhengbo.(2022).Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients.CANCER MEDICINE.
MLA	Hao, Yue,et al."Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients".CANCER MEDICINE (2022).